Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vigabatrin for tuberous sclerosis complex.

P Curatolo1, M Verdecchia, R Bombardieri

  • 1Department of Neurosciences, Pediatric Neurology, Tor Vergata University, Via di Tor Vergata 135, 00133 Rome, Italy. curatolo@uniroma2.it

Brain & Development
|November 10, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnosis of pediatric anti-NMDAR encephalitis at the onset: A clinical challenge.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society·2020
Same author

Electrochemotherapy in the treatment of cutaneous malignancy: Outcomes and subgroup analysis from the cumulative results from the pan-European International Network for Sharing Practice in Electrochemotherapy database for 2482 lesions in 987 patients (2008-2019).

European journal of cancer (Oxford, England : 1990)·2020
Same author

Model of care and risk factors for poor outcomes in patients on multi-drug resistant tuberculosis treatment at two facilities in eSwatini (formerly Swaziland), 2011-2013.

PloS one·2018
Same author

Electrochemotherapy of unresectable cutaneous tumours with reduced dosages of intravenous bleomycin: analysis of 57 patients from the International Network for Sharing Practices of Electrochemotherapy registry.

Journal of the European Academy of Dermatology and Venereology : JEADV·2017
Same author

Electrochemotherapy in the treatment of metastatic malignant melanoma: a prospective cohort study by InspECT.

The British journal of dermatology·2017
Same author

Treatment efficacy with electrochemotherapy: A multi-institutional prospective observational study on 376 patients with superficial tumors.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2016
Same journal

Receptor-specific dopaminergic imbalance and sensory gating in Lesch-Nyhan syndrome.

Brain & development·2026
Same journal

From weather stations to the home environment: Refining seizure prediction in pediatric drug-resistant epilepsy.

Brain & development·2026
Same journal

Pediatric GBS-myelitis overlap syndrome: Severe phenotype, treatment response, and neurological outcomes.

Brain & development·2026
Same journal

Aspartoacylase (ASPA) gene mutations and neuroimaging features in Iranian patients with Canavan disease: a descriptive study.

Brain & development·2026
Same journal

Third nationwide survey of bilirubin encephalopathy in preterm infants in Japan.

Brain & development·2026
Same journal

Urine protein/osmolality and creatinine/osmolality ratios for assessing proteinuria and motor function in children with spinal muscular atrophy.

Brain & development·2026
See all related articles

Vigabatrin effectively treats infantile spasms, especially in tuberous sclerosis (TSC) patients, by enhancing GABAergic transmission. However, it can cause visual-field defects, necessitating further research into optimal treatment durations.

Area of Science:

  • Neurology
  • Pharmacology
  • Genetics

Background:

  • Infantile spasms (IS) are a severe epilepsy syndrome.
  • Tuberous sclerosis (TSC) is a genetic disorder often associated with IS.
  • Current IS treatments have limitations, highlighting the need for effective therapies.

Purpose of the Study:

  • To evaluate Vigabatrin (VGB) as a treatment for infantile spasms.
  • To investigate the efficacy of VGB in TSC-associated IS.
  • To explore the underlying mechanisms and potential side effects of VGB.

Main Methods:

  • Review of existing literature on VGB for infantile spasms.
  • Analysis of VGB's pharmacological action on GABAergic neurotransmission.
  • Assessment of VGB's clinical efficacy and safety profile, particularly in TSC.

Related Experiment Videos

Main Results:

  • VGB is highly effective in reducing infantile spasms in ~50% of patients.
  • VGB achieves near-complete spasm cessation in up to 95% of TSC-associated IS cases.
  • Treatment cessation of spasms correlates with improved behavior and development.

Conclusions:

  • VGB is a first-line monotherapy for IS in infants with TSC.
  • The mechanism of VGB's efficacy in TSC may involve GABAergic pathway impairment.
  • VGB use is associated with visual-field defects in up to 50% of patients, requiring further investigation into safe treatment durations.